Saturday 17 October 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.9% and free cash flow fell 600.4%, each against the same quarter a year earlier.
1.70
0.17
−9.09%
Follow CNTN
Canton Strategic Holdings, Inc. (CNTN) P/E ratio
As of 16 October 2026, Canton Strategic Holdings, Inc. (CNTN) trades at a P/E ratio of 9.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 15.6× (July 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 14.9× | — |
Against its own ten years
Low 0.0×
High 15.6×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MDWD MediWound Ltd. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CDXS Codexis, Inc. compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| NBP NovaBridge Biosciences compare | n/m |
| CNTN Canton Strategic Holdings, Inc. | 9.0× |
| MENS Jyong Biotech Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)